Prognosis and prognostic factors in patients with hypertrophic cardiomyopathy in Japan: results from a nationwide study

Objective: To investigate prognosis and prognostic factors in patients with hypertrophic cardiomyopathy (HCM) in Japan. Design: A nationwide epidemiological study. Setting: Hospitals selected randomly from among all hospitals in Japan. Patients: Clinical and epidemiological information for 2155 patients with HCM were collected in 1999. Main outcome measures: Patients were classified on the basis of baseline prognostic factors. Survival rates up to 5 years were calculated by Cox’s proportional hazard model for 1605 patients. Results: During the follow-up period, 241 deaths were recorded. The crude 5-year survival rate for the entire cohort was 86% (95% CI 84 to 88), and annual mortality ranged from 2.2% to 3.0%. A higher cardiothoracic ratio on chest x ray (HR 1.61; 95% CI 1.26 to 2.05, with 1 SD (6.2%) increase), a lower left ventricular ejection fraction (HR 1.42; 95% CI 1.20 to 1.69, with 1 SD (13%) decrease) and the presence of left bundle branch block (HR 3.14; 95% CI 1.28 to 7.71) were independently associated with a poorer prognosis, whereas the presence of apical hypertrophy at baseline (HR 0.58; 95%CI 0.36 to 0.92) predicted a better chance of survival. Conclusions: The nationwide survey of patients with hypertrophic cardiomyopathy yielded important information on its prognosis and prognostic factors. These observations afford, for the first time, a measure of risk stratification in patients with HCM in Japan.

[1]  B. Maron,et al.  Relation between extent of left ventricular hypertrophy and occurrence of sudden cardiac death in hypertrophic cardiomyopathy. , 1990, Journal of the American College of Cardiology.

[2]  N. Smedira,et al.  Conduction system abnormalities in patients with obstructive hypertrophic cardiomyopathy following septal reduction interventions. , 2004, The American journal of cardiology.

[3]  C. Kawai,et al.  Report of the WHO/ISFC task force on the definition and classification of cardiomyopathies. , 1980, British heart journal.

[4]  B. Maron,et al.  Clinical course of hypertrophic cardiomyopathy with survival to advanced age. , 2003, Journal of the American College of Cardiology.

[5]  B. Maron Hypertrophic cardiomyopathy: a systematic review. , 2002, JAMA.

[6]  R. Kwong,et al.  Apical hypertrophic cardiomyopathy: diagnosed by cardiac magnetic resonance imaging. , 2006, Texas Heart Institute journal.

[7]  B. Maron,et al.  Impact of Atrial Fibrillation on the Clinical Course of Hypertrophic Cardiomyopathy , 2001, Circulation.

[8]  A. Matsumori,et al.  Epidemiology of idiopathic cardiomyopathy in Japan: results from a nationwide survey , 2002, Heart.

[9]  F. Triposkiadis,et al.  Hypertrophic cardiomyopathy in Greece: clinical course and outcome. , 1998, Chest.

[10]  B. Maron,et al.  Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. , 2000, The New England journal of medicine.

[11]  B. Maron Hypertrophic cardiomyopathy: an important global disease. , 2004, The American journal of medicine.

[12]  B. Maron,et al.  Impact of patient selection biases on the perception of hypertrophic cardiomyopathy and its natural history. , 1993, The American journal of cardiology.

[13]  J. Webb,et al.  Apical hypertrophic cardiomyopathy: clinical follow-up and diagnostic correlates. , 1990, Journal of the American College of Cardiology.

[14]  A. Matsumori,et al.  Epidemiologic and clinical characteristics of cardiomyopathies in Japan: results from nationwide surveys. , 2002, Circulation journal : official journal of the Japanese Circulation Society.

[15]  H. Morita,et al.  Relationship between oxidative stress and systolic dysfunction in patients with hypertrophic cardiomyopathy. , 2005, Journal of cardiac failure.

[16]  B Maisch,et al.  Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. , 1996, Circulation.

[17]  M. Eriksson,et al.  Long-term outcome in patients with apical hypertrophic cardiomyopathy. , 2002, Journal of the American College of Cardiology.

[18]  T. Nakano,et al.  Prognosis of completely asymptomatic adult patients with hypertrophic cardiomyopathy. , 1999, Journal of the American College of Cardiology.

[19]  P. Elliott,et al.  Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy , 2001, The Lancet.

[20]  M. Desai,et al.  Management of hypertrophic cardiomyopathy. , 1993, Heart disease and stroke : a journal for primary care physicians.

[21]  K. Kawecka-Jaszcz,et al.  Sex-based comparison of survival in referred patients with hypertrophic cardiomyopathy. , 2004, The American journal of medicine.

[22]  C. Lau,et al.  Clinical characteristics of and long-term outcome in Chinese patients with hypertrophic cardiomyopathy. , 2004, The American journal of medicine.

[23]  C. Tei,et al.  Asymmetric apical hypertrophy: ten years experience. , 1986, Postgraduate medical journal.

[24]  K. Yano,et al.  Clinical analysis of hypertrophic cardiomyopathy which evolved into dilated phase during long-term follow-up. , 1999, Japanese heart journal.

[25]  B. Maron,et al.  Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. , 1999, JAMA.

[26]  Iacopo Olivotto,et al.  Maximum left ventricular thickness and risk of sudden death in patients with hypertrophic cardiomyopathy. , 2003, Journal of the American College of Cardiology.

[27]  W. Williams,et al.  Hypertrophic cardiomyopathy. Clinical spectrum and treatment. , 1995, Circulation.

[28]  M. Burch,et al.  Hypertrophic cardiomyopathy. , 1994, Archives of disease in childhood.